Anteris Submits Confidential Draft Registration Statement for Proposed US IPO

Anteris Technologies Ltd has submitted a confidential draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") by its affiliate, Anteris Technologies Global Corp. (“Anteris Global”), relating to the proposed U.S. initial public offering by Anteris Global of its shares of common stock (the “Proposed Offering”).

The number of shares of common stock to be offered and the price range for the Proposed Offering have not been determined. The Proposed Offering is expected to occur after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued pursuant to and in accordance with Rule 135 under the Securities Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813095659/en/

Investor Relations

Debbie Ormsby

[email protected]

Anteris Technologies Ltd

+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.

Managing Director

Blueprint Life Science Group

+1 917 330 4269

Source: Anteris Technologies Ltd

You May Also Be Interested In

• Parabilis Medicines closes $770.5 million IPO and concurrent private placement
• AES prices $1 billion senior notes offering with 2029 and 2033 maturities
• Enliven Therapeutics launches $250 million public stock offering